Oppenheimerfunds, Inc. reports that it decreased its ownership in Boston Scientific Corp stock by 404,147 shares in a 13F filing with the SEC.
In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific Corporation stock in a transaction on Wednesday, November 1st. Capital World Investors lifted its holdings in shares of Boston Scientific Corporation by 1.6% in the second quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider's stock valued at $138,928,000 after acquiring an additional 2,850,630 shares in the last quarter.
As of quarter end California State Teachers Retirement System had disposed of a total of 223,594 shares trimming its position 8.8%. Amalgamated Bank expanded its investment by buying 3,580 shares an increase of 2.2% as of 09/30/2017. Vanguard Group Inc. increased its stake in shares of Boston Scientific Corporation by 2.8% in the second quarter. Janus Henderson Group PLC increased its stake in shares of Boston Scientific Corporation by 22,491.6% in the second quarter. Over a month, it has seen its stock price volatility to stay at 1.65% while shortening the period to a week, volatility was 1.6%.
As of the end of the quarter Icon Advisers Inc/co had bought a total of 52,100 shares growing its stake by 21.3%.
Cubist Systematic Strategies LLC Takes Position in Shaw Communications Inc. (SJR)
CIBC raised their target price on shares of Shaw Communications from C$29.00 to C$31.00 in a research note on Thursday, June 29th. Finally, Bank of America Corp DE raised its stake in shares of Shaw Communications by 22.8% during the first quarter.
Boston Scientific Corporation (NYSE:BSX) recent drop took place on significantly more volume which surged almost 6.53 million contracts on 10-Nov-17 versus its daily average of 5.24 million. On October 31 analysts at SunTrust Banks released research on BSX stating a rating of "Buy" and establishing a price target of $34.00.
BMO Capital Markets raised the price target on October 27 changing the forecast from $30.00 to $32.00 and issued a "Outperform" rating. Canaccord Genuity initiated coverage on shares of Boston Scientific Corporation in a report on Tuesday, October 24th. Leerink Swann reaffirmed a buy rating on shares of Boston Scientific Corp.in a report on Friday, July 29th. On October 3 Needham & Company LLC maintained a stock rating of "Buy" targeting a price of $32.00. The first sale was made at $28.5 but later the stock became weaker, and closed with a fall of -0.8%.
Deep diving into the technical levels for Boston Scientific Corp (BSX), we note that the equity now has a 14-day Commodity Channel Index (CCI) of 15.51.
Boston Scientific Corporation (NYSE:BSX) touched its 1-Year High price of $29.93 on 10/23/17 and its 1-Year Low price of $19.67 on 12/01/16. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.
Stifel Nicolaus Reiterates Hold Rating for Eaton Corporation, PLC (NYSE:ETN)
The stock of Activision Blizzard, Inc. (NASDAQ:MXIM) has "Hold" rating given on Friday, October 13 by RBC Capital Markets. The firm has "Hold" rating given on Wednesday, October 11 by SunTrust. (NYSE:FR) on Monday, November 2 with "Buy" rating.
Boston Scientific Corporation, BSX from Healthcare exhibited a market capitalization of 39.38B. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business's revenue for the quarter was up 5.6% compared to the same quarter previous year. As of the latest earnings report the EPS was $0.61 with 1.37B shares presently outstanding.
Boston Scientific Corporation (BSX) have shown a high EPS growth of -2.80% in the last 5 years and has earnings rose of 241.40% yoy. Separately, EVP & President, MedSurg Phalen Michael P. Sell 15500 shares of the company at a price of $28.42 on 2017-10-30. Institutional investors own 90.50% of the company's stock. The shares were sold at an average price of $23.90, for a total transaction of $59,750.00. Amalgamated Bank now owns 165,040 shares valued at $4,814,000. The Average Volume of the company is 5.24 Million, while the Volume of the company in the last trading session was 6.53 Billion.
The Insider ownership of firm was 0.10%, which can be took as alarming gauge.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald.
Oppenheimerfunds, Inc. Modifies Its Stake in Coca-Cola Enterprises (CCE)
Independent Portfolio Consultants Inc. lifted its holdings in Coca-Cola Company (The) by 1,065.9% during the first quarter. Ar Asset Management Inc holds 0.45% of its portfolio in Coca-Cola European Partners plc Ordinary Shares for 27,000 shares.
The company's products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.